New England Journal of Medicine: C. diff burden down 25%

New England Journal of Medicine: C. diff burden down 25%

While the deadly pathogen on everyone’s minds might be Coronavirus, it’s important to continue the fight against HAIs, most notably C. difficile, which is among the deadliest. However, a recent Becker’s Hospital Review article hails a New England Journal of Medicine report showing the national C. diff burden dropped by almost 25% over 5 years. 

There are many reasons for this phenomenal drop including a sharper focus on overall hospital IP and increased hand washing protocols across healthcare systems. Another mitigating factor is likely the increased use of UVC disinfection throughout hospitals.  A UV Disinfection system administers ultraviolet light needed to eradicate harmful pathogens. When bundled with manual cleaning and other disinfection protocols, the technology significantly reduces the presence of patient exposure to HAIs, like the reduction outlined in the NEJM report.

When it comes to fighting any healthcare-associated infections (HAIs), especially those as deadly as C. diff, choosing the right UVC technology is paramount.The technology only proves effective when it delivers the exact dose necessary to kill the specific microorganisms that cause infections.  RD UVC is the only system that confirms the actual lethal UVC dose for C.diff  is delivered, proving compliance with IP protocol.

A Clostridium difficile Spore Inactivation Study Using Ultraviolet-C Energy conducted by Moog Medical Devices Group (MMDG) Life Science Laboratories sought to determine inactivation rates for Clostridium difficile spores using ultraviolet-c (UV-C) energy generated and measured by the RD™ UVC System and its remote “challenge devices” sensors.  The study scientifically confirmed that the RD UVC technology was highly effective in reducing C. diff spores on contaminated surfaces.  In fact, the RD UVC system is the only mobile UVC disinfector to date that has used a microbiology laboratory to verify and publish a third-party study using quantitative UVC doses to effectively kill C. diff.  The system works by measuring actual UVC dosage via multiple remote sensors placed throughout a hospital environment.  It also automates calculations and utilization, ensuring IP teams have the proof of compliance data it needs for efficacy reports required by government auditors and payor partners.


See How RD UVC Can Help Eradicate C. Diff, Coronavirus, and Other Harmful Pathogens in Your Hospital

Get More Info